Cell-based Assays
dep. Head of Department Pharma & Biotech
Group Leader Cell- & Molecular Biology
With a long-standing commercial track record in cell-based research, we have established a wide range of cell-based assay options, and we cover both established assays and assay development.
We offer
- A broad choice of cell lines and primary models, covering multiple disease indications (oncology, metabolic diseases, cardiovascular etc.), plus custom stable cell lines
- Specialist expertise in the oncology context, including immuno-oncology assays
- Compound and combination treatments, up to small libraries
- Deep understanding and experience in gene silencing assays using shRNAs and siRNAs
- Standard and custom homogenous plate reader assays (proliferation, apoptosis etc.)
- Label-free impedance measurements
- Fixed-endpoint and live high-content microscopy assays
- Confocal microscopy and FACS analyses
- Single and multiplexed RT-qPCR assays; Quantstudio platform for pre-designed or custom panels of up to 900 genes
- Add-on protein profiling assays (e.g., cellular pathway mapping, cytokines from cell supernatants)
We provide innovative cellular screening technologies for biomedical research and preclinical drug development. Our portfolio combines advanced biochemical with sophisticated microscopy analyses, making use of the versatile Chromobody® technology by ChromoTek GmbH.
Chromobodies® are single domain antibodies genetically fused to fluorescent proteins serving as functional nanoprobes in living cells. The Chromobody technology allows for the first time to trace endogenous intracellular antigens and to visualize dynamic changes of these targets upon intrinsic or extrinsic stimuli in living cells. In addition, Chromobodies can be applied for intracellular target screening and validation processes.
Our expertise
-
Translocation assays (e.g. to screen kinase inhibitors in living cells)
-
Cell cycle analysis
-
Phenotypic screening
-
Signal pathway analysis
-
Target screening and validation
We provide ready-to-go cell linesto monitor:
-
The full cell cycle
-
Apoptotic events
-
Morphological changes of the cytoskeleton
-
Further cellular markers are currently under development.
To serve individual customer needs, we generate custom single domain antibodies (sdAbs) and chromobodies in our sdAb facility.
We offer
-
Antigen production for biopanning / immunization
-
SdAb library screening by phage display
-
Biochemical validation / characterization of identified sdAbs
-
Recombinant production of sdAbs
-
Generation of Chromobodies® for intracellular applications
-
Cell lines and primary cells with stable lentiviral Chromobody® expression, ready-to-use or on demand
We employ inter alia lentiviral vectors to down-regulate the gene expression of target genes via shRNA-mediated RNA interference (RNAi). Alternatively, we use commercially available siRNAs for cell-based RNAi gene silencing experiments.
We offer
-
Generation of lentivirus encoding target-specific shRNAs
-
Production of stable knock-down cell lines
-
Validation of target silencing by RT-qPCR, Western blot and/or immunofluorescence microscopy
-
RNAi studies with shRNAs or siRNAs, using a wide range of reader-based and fixed endpoint or live microscopy assays
A further expansion of possibilities is provided by the CRISPR/Cas9 technology, which we employ to abrogate target expression.
More Services
NMI Technologie Transfer GmbH
Markwiesenstraße 55, 72770 Reutlingen
Tel.: +49 7121 51530-0
Mail:
info@nmi-tt.de
NMI on Social Media
Follow us now
